Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Theralase Technologies Inc. > Heliyon Published 15 June 2024,
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(374)
•••
Comment by CancerSlayeron Jun 17, 2024 10:27am
147 Views
Post# 36091964

RE:RE:Heliyon Published 15 June 2024,

RE:RE:Heliyon Published 15 June 2024,
wildbird1 wrote:


Oden6570 great find...

The big question? Is the government of Canada involved?

The answer is in the list of experts that worked on the project.
Darwyn Kobasa... Special pathogens program, National Microbiology Laboratory, Public health Agency Of Canada.

In this link...
https://science.gc.ca/site/science/en/blogs/science-health/keeping-eye-bird-flu

It is said '' Darwyn Kobasa and the National Microbiology Laboratory of Canada, are working with academic partner (could be TLT) to test potential vaccine and treatments for Bird-Flu''.

Does anybody smell a possible grant?






Thanks Wildbird...I'm certainly smelling a grant...could possibly explain the confidence in raising $10 million?

Per the June 4, 2024 release from Theralase:

"The research was completed at the laboratory of Kevin Coombs, Ph.D., University of Manitoba in conjunction with National Microbiology Laboratory and Theralase® Technologies Inc."



<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities